Vilya的动态

Did you know that cell avidity, a measure of binding strength between cells, can be used to identify CAR-T products that are both potent and safe? Dr. Yufei (Sophie) Wang and Professor Wayne Marasco from Dana Farber Cancer Institute?recently published in Molecular Cancer and identified a highly efficacious anti-CAIX CAR without any concerning OTOT toxicity, resulting in an immunotherapeutic product that can now be specifically and safely applied in the clinic. Find the study here: https://bit.ly/3wpJen4

#cancersmdpi ?? New paper alert! Our latest #review explores *Extracellular Vesicle- and Mitochondria-Based Targeting of Non-Small Cell Lung Cancer Response to Radiation*. Dive into the challenges and perspectives in this field. ????By Sergey Leonov et al Yulia Merkher Read it here: https://lnkd.in/dcNVY6DA

A hallmark of cancer refers to a defining characteristic that enables the growth and survival of cancer cells. These include traits like sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, and the ability to metastasize. Understanding these hallmarks is crucial for developing targeted therapies, as they represent the biological mechanisms driving tumor development and progression. Each hallmark highlights specific vulnerabilities that can be exploited for therapeutic intervention, forming the foundation for modern cancer research and treatment strategies.

Cannabinoids and oral care? YES! #cannabis #dental #oralhealth #dentalhygienist #dentalhealth #teethcare #cannabinoids #cannabiscommunity #cannabiseducation #cannabismedicinal #dentists #plantmedicine #naturalhealth #naturalmedicine

We are excited to share the publication of our #SOS1 manuscript as the cover of the April Molecular Cancer Therapeutics journal, published by the American Association for Cancer Research. The article details the discovery of our SOS1 bifunctional degraders?and their target-dependent effects in multiple KRAS mutant models. Not only did BTX-6654 demonstrate tumor growth inhibition in KRAS G12C xenograft models, but it also exhibited synergistic effects with #KRAS and #MEK inhibitors. https://lnkd.in/gSHG6MQu

Real-Time Metabolic Analysis for Cancer Research Agilent Seahorse XF technology The Agilent Seahorse XF platform provides functional measurements of two primary metabolic pathways—glycolysis and oxidative phosphorylation—from live cells in real time. This technology enables the phenotypic evaluation of cancer cells in response to different metabolic substrates or inhibitors. https://lnkd.in/gqg5hMAT

One of the many reason's our technology works so well is our unique ability to control / fine-tune the stiffness of the culture matrix = better recapitulations of the tumor microenvironment. If you are interested in learning more about this ovarian cancer research, message me and I can send over the case study information while we have a chat!

RASTRUM: Redefining Tumor Microenvironment Research One of the most groundbreaking capabilities of RASTRUM matrices is the ability to fine-tune the stiffness of the tumor microenvironment, unlocking conditions that closely mimic in vivo settings. In ovarian cancer research, for example, replicating a “stiff” environment provides invaluable insights—like enhanced cell proliferation, metabolic shifts, and changes in spheroid structure—that simply don’t occur in softer conditions. This level of customization with RASTRUM marks a significant advancement in how we approach complex cancer research. Curious about what RASTRUM can do for your research? Connect with our team today to discover the possibilities. ??

Did you see our WRN PCC Nomination announcement today? Check out this new paper that was published today (not our paper) and is very relevant to WRN. The paper provides mechanistic insights into the role of WRN in DNA end resection and homologous recombination, particularly in the context of BRCA1-BARD1's enhancement of WRN's helicase activity. It does not explicitly advocate for WRN inhibition as a therapeutic strategy for cancer. But it focuses on how WRN, together with BRCA1-BARD1, CtIP, and MRN complexes, contributes to DNA repair processes. https://lnkd.in/gRhMj_YT

Remember when we posted last week about how important both your detection and concentration methods are for low concentration samples? Liquid biopsies are the perfect example that require the highest performing workflows for detecting cancer mutations such as KRAS. Get the most out of your cancer research samples by combining our ultrasensitive oncology assays with the Ceres NEAT Biopsy Kit. Request our App Notes or this one from Ceres Nanosciences and learn more here: https://lnkd.in/eiv9xThW ? #CeresNeat #GTMolecular #KRASdetection #CancerResearch #LiquidBiopsy #PCR #dPCR #digitalPCR #QIAcuity Ceres Nanosciences, Inc. QIAGEN Research use only. Not intended for diagnostic purposes.